BRAF and neoplasm: For example, a BRAF inhibitor, when combined with an anti-PD-1 or anti-PD-L1 antibody, can increase the number and activity of tumor-infiltrating lymphocytes (TILs) in melanoma, leading to improved tumor control and patient survival 9.